ILUMYA is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Sun Pharmaceutical Industries, Inc.. The primary component is Tildrakizumab.
Product ID | 47335-177_38b1fe34-2474-48a6-8d80-ce4abdaed9d6 |
NDC | 47335-177 |
Product Type | Human Prescription Drug |
Proprietary Name | ILUMYA |
Generic Name | Tildrakizumab-asmn |
Dosage Form | Injection, Solution |
Route of Administration | SUBCUTANEOUS |
Marketing Start Date | 2018-08-06 |
Marketing Category | BLA / BLA |
Application Number | BLA761067 |
Labeler Name | Sun Pharmaceutical Industries, Inc. |
Substance Name | TILDRAKIZUMAB |
Active Ingredient Strength | 100 mg/mL |
Pharm Classes | Interleukin-23 Antagonist [EPC],Interleukin-23 Antagonists [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2020-12-31 |
Marketing Start Date | 2018-08-06 |
NDC Exclude Flag | N |
Sample Package? | Y |
Marketing Category | BLA |
Application Number | BLA761067 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2018-08-06 |
Marketing Category | BLA |
Application Number | BLA761067 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2018-08-06 |
Marketing Category | BLA |
Application Number | BLA761067 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2018-08-06 |
Marketing Category | BLA |
Application Number | BLA761067 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2018-08-06 |
Ingredient | Strength |
---|---|
TILDRAKIZUMAB | 100 mg/mL |
SPL SET ID: | c6a322bb-51b9-4f0e-8642-62a9682ffcde |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
ILUMYA 90644697 not registered Live/Pending |
Sun Pharma Global FZE 2021-04-14 |
ILUMYA 87835715 5657826 Live/Registered |
Sun Pharma Global FZE 2018-03-15 |
ILUMYA 87459018 not registered Dead/Abandoned |
Sun Pharma Global FZE 2017-05-22 |
ILUMYA 87358465 not registered Live/Pending |
Sun Pharma Global FZE 2017-03-04 |